Skip to content
DataLookout
Menu

NCT03554174

Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 16 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 11 words
    • Study completion pushed from Sep 2026 to Dec 2026
    • Secondary endpoints: details revised at 2 of 3 entries
  2. Minor Study completion date: Sep 2025 to Sep 2026v17
  3. Minor Study completion date: Jun 2025 to Sep 2025v16
  4. Minor Study completion date: Apr 2025 to Jun 2025v15
  5. Minor Primary completion date changed from estimate of Feb 27, 2024 to Jul 8, 2021
    • Study completion date: Apr 2024 to Apr 2025
    v14
Show 10 earlier versionsHide 10 earlier versions
  1. Notable Primary completion date: Feb 27, 2023 to Feb 27, 2024
    • Study completion date: Apr 2023 to Apr 2024
    v13
  2. Notable Primary completion date: Jun 2022 to Feb 27, 2023
    • Start date: Jun 30, 2018 to Feb 27, 2018
    • Secondary endpoints: 7 to 3
    v12
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v11
  4. Notable Primary completion date: Jun 2021 to Jun 2022
    • Site contact updated
    v10
  5. Minor Primary completion date: Apr 2021 to Jun 2021v9
  6. Minor Site contact updatedv7
  7. Minor Site contact updatedv6
  8. Minor Site contact updatedv4
  9. Minor Site contact updatedv3
  10. Minor Start date changed from estimate of Jun 2018 to Jun 30, 2018v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Changes in electrical brain activity associated with neuroplasticity measured by Electroencephalography (EEG)
Timeframe: One day and two weeks after each experimental session

Secondary (3)

Changes in verbal memory [ Time Frame: One day and two weeks after each experimental session ]
Change in mood symptoms using the GRID-Hamilton Depression Rating Scale (GRID-HAM-D)
Change in mood symptoms using the Quick Inventory of Depressive Symptoms (QIDS-SR16)

Arms and interventions

Placebo/Low Dose PsilocybinExperimental

Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.

Placebo/Medium Dose PsilocybinExperimental

Subjects in this arm receive placebo in the first session and medium dose psilocybin in the second session.

Low Dose Psilocybin/PlaceboExperimental

Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.

Medium Dose Psilocybin/PlaceboExperimental

Subjects in this arm receive medium dose psilocybin in the first session and placebo in the second session.

Drugs: Low Dose Psilocybin, Placebo, Medium Dose Psilocybin

Sites

1 site in 1 country

  • VA Connecticut Healthcare System, West Haven CampusWest Haven, Connecticut, United States